In 2005, Euglena Co. based in Tokyo, Japan succeeded to mass-produce euglena, microalgae, outside first time in the world. This tiny euglena has a huge potential to battle with one of the world's biggest challenge – climate change; it can be a food to nourish growing populations, and it can be a fuel to fly an airplane.
Celgene has been one of the dominant biotech players in recent history. Its successful R&D and acquisitions have made the company a contender for the industry’s pole position, and its growing commercialization capabilities have effectively utilized its assets to create a diversified growth profile with a 2020 sales CAGR of almost 20%.
By investing in in-house drug research and development, partnering with world class research institutes, and acquiring high potential compounds, Celgene has achieved massive success so far and is positioned to continue to do so.
How the business, R&D, and manufacturing synergies of the Swiss drug giant helped it to become the largest biotech manufacturer in the world.
Data! Robots! Microbes! The revolution is coming!
Baxalta is a leading biopharmaceutical company, delivering innovative products to patients around the world in difficult to treat therapeutic areas
Moderna is a pioneer in the revolutionary new field of RNA therapetutics – a technology which allows the human body to help heal itself. No only are they delivering a new technology, but they're doing it in a novel way. Remember Wyeth Pharmaceuticals? They took 4-7 years to discover a new drug target and begin preclinical testing. Moderna does it in a matter of weeks.
Gilead Sciences is one of the top-performing companies in the biotechnology industry with an operating model that combines R&D with M&A strategies.
The business model for biotech is simple: discover and develop therapies and sell them at high-enough margins to justify the costs until the patent expires. The larger the unmet need and the more effective the therapy, the more value is […]
Valeant Pharmaceuticals has introduced a new operating model in R&D based on mergers and premium pricing. Is it sustainable?
